Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates circulating in Beijing, China

PLoS One. 2015 Mar 17;10(3):e0120035. doi: 10.1371/journal.pone.0120035. eCollection 2015.

Abstract

Background: To investigate the serotypes, antibiotic susceptibilities, and multi-locus sequence type (MLST) profiles of Streptococcus agalactiae (S. agalactiae) in Beijing to provide references for the prevention and treatment of S. agalactiae infections.

Methods: All isolates were identified using the CAMP test and the latex-agglutination assay and serotyped using a Strep-B-Latex kit, after which they were assessed for antibiotic susceptibility, macrolide-resistance genes, and MLST profiles.

Results: In total, 56 S. agalactiae isolates were identified in 863 pregnant women (6.5%). Serotypes Ia, Ib, II, III, and V were identified, among which types III (32.1%), Ia (17.9%), Ib (16.1%), and V (14.3%) were the predominant serotypes. All isolates were susceptible to penicillin and ceftriaxone. The nonsusceptiblity rates measured for erythromycin, clarithromycin, azithromycin, telithromycin, clindamycin, tetracycline, and levofloxacin were 85.7%, 92.9%, 98.2%, 30.4%, 73.2%, 91%, and 39.3%, respectively. We identified 14 sequence types (STs) for the 56 isolates, among which ST19 (30.4%) was predominant. The rate of fluoroquinolone resistance was higher in serotype III than in the other serotypes. Among the 44 erythromycin-resistant isolates, 32 (72.7%) carried ermB.

Conclusion: S. agalactiae isolates of the serotypes Ia, Ib, III, and V are common in Beijing. Among the S. agalactiae isolates, the macrolide and clindamycin resistance rates are extremely high. Most of the erythromycin-resistant isolates carry ermB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics*
  • China
  • Drug Resistance, Microbial*
  • Erythromycin / pharmacology
  • Serogroup*
  • Streptococcus agalactiae / drug effects
  • Streptococcus agalactiae / genetics
  • Streptococcus agalactiae / isolation & purification*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Erythromycin

Grants and funding

This study was financially supported by the Research Funds of Profession Quota Budget from Beijing Municipal Science and Technology Commission (2014-bjsekyjs-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.